Skip to content
Open access

Combined siRNA Targeting IκBα and Stat6 Promotes Macrophage Reprogramming toward Cancer Immunotherapy.

Sep 2026 · Molecular Pharmaceutics · Vol 23 11, pp. 5426-5435 · 0 citations · 50 references
Medicine

TL;DR

This data demonstrates that this dual-targeting strategy strongly induced potent reprogramming of M2-polarized macrophages, establishing it as a superior immunotherapeutic framework.

Abstract

Tumor-associated macrophages (TAMs) are central regulators of the tumor microenvironment (TME). Their polarization state can critically influence tumor development and treatment resistance. In the TME, the pro-tumor M2-like phenotype is the most prevalent among TAMs and contributes to tumor progression by promoting immunosuppression, angiogenesis, and metastasis. Thus, reprogramming TAMs from an M2 to an antitumor M1-like phenotype is a promising strategy to enhance cancer immunotherapy by inhibiting these processes, stimulating inflammatory responses, and activating cytotoxic immune cells. In this study, an array of small interfering RNA (siRNA) targeting candidate genes to repolarize macrophages, i.e., the inhibitor of nuclear factor kappa B alpha (IκBα), the colony-stimulating factor 1 receptor (Csf-1r), and the signal transducer and activator of transcription 6 (Stat6), was delivered by lipid nanoparticles (LNPs). While knockdown of all targeted genes was successful, silencing IκBα or Stat6 altered M1/M2 marker expression toward an M1-like polarization. Furthermore, combining IκBα and Stat6 produced the most effective macrophage reprogramming, achieving simultaneous downregulation of M2 markers and upregulation of M1 markers. Our data demonstrates that this dual-targeting strategy strongly induced potent reprogramming of M2-polarized macrophages, establishing it as a superior immunotherapeutic framework.

Read PDF

Similar papers

Review Sep 2026

Immunogenic Cell Death-Associated miRNAs in the Tumor Microenvironment of Hepatocellular Carcinoma.

Hepatocellular carcinoma (HCC) poses significant therapeutic challenges due to its high heterogeneity and immunosuppressive tumor microenvironment (TME). Immunogenic cell death (ICD) represents a promising strategy in cancer therapy by eliciting antitumor immune responses through the controlled release of damage-associ...

An-Rong Jiang, Yun Mo, Ying Wang et al. · 0 citations
Oct 2026

Epigenetic Priming Sensitizes Metastatic Breast Cancer to Checkpoint Blockade by Rewiring the Tumor-Immune Microenvironment.

Work using metastatic mouse models shows that the antitumor response is multifactorial, comprising downregulation of myeloid-mediated CD8+ T-cell suppression along with increased B-cell and plasma cell activation, antibody production, and tertiary lymphoid structure (TLS) maturation.

Y. Senent, R. Manguso · 0 citations
Review Open access Oct 2026

Molecular basis for developing tumor-targeted siRNAs for future immunotherapy.

By silencing genes involved in immune suppression, siRNAs can restore T cell activation and improve the efficacy of cancer vaccines and adoptive cell therapies, however, significant challenges remain.

M. Sioud · 0 citations
Open access Aug 2026

miR-155-5p drives coordinated tumor and macrophage reprogramming across multiple cancer entities

Investigation of whether miR-155-5p and miR-3535 represent regulators capable of driving coordinated functional reprogramming of both, tumor cells and macrophages found they modulate tumor-intrinsic immune checkpoint expression and functional macrophage polarization in a coordinated way.

Theresa Kordaß, Ann-Katrin Schlosser, Marijan Czygan et al. · 0 citations
Review Open access Sep 2026

Smart nanodelivery systems targeting tumor-associated macrophage reprogramming to potentiate cancer immunotherapy: pharmacological mechanisms, delivery strategies and translational perspectives

Smart nanodelivery systems can improve the in vivo stability, tumor accumulation, TAM exposure, and spatiotemporal release of immunomodulators, small-molecule inhibitors, nucleic acid therapeutics, cytokines, and macrophage immune-checkpoint modulators, thereby improving efficacy while reducing systemic toxicity.

Xian-G. Sun, Chen-Chen Chu, Jia-Jie Wang · 0 citations
Open access Aug 2026

NF-κB-driven immune checkpoint knockdown and cytokine expression in cancer cells for tumor immunotherapy

A tumor-selective, safe therapeutic gene cassette specifically activated by NF-κB to produce cytokine IL-15 and microRNAs silencing two key immune checkpoints, PD-L1 and CD47, is constructed and shows significant antitumor effects, favorable tumor selectivity, and biosafety across multiple murine solid tumor models.

Yi-Le Wang, Zi-Yan Kong, Yun-Qi Zhao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.